NCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT04644211 2026-01-08
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
Phase 2 Recruiting
NCT02577926 2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2 Active not recruiting
NCT01375140 2025-06-08
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05870475 2024-07-03
PV
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT01981850 2022-01-05
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
Phase 2 Completed
NCT03669965 2020-07-31
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Kartos Therapeutics, Inc.
Phase 2 Unknown
NCT02267278 2019-06-12
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
M.D. Anderson Cancer Center
Phase 2 Completed